We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




GE Healthcare To Acquire Whatman

By HospiMedica staff writers
Posted on 12 Feb 2008
GE Healthcare (Chalfont St. More...
Giles, UK), a unit of General Electric Co., and Whatman plc (Maidstone, UK) have reached agreement on the terms of a recommended acquisition of Whatman by GE Healthcare.

Under the terms of the transaction, each Whatman shareholder will receive GBP 2.70 in cash for each Whatman share, valuing Whatman at approximately GBP 363 million. The transaction is subject to shareholder as well as customary regulatory approvals.

Whatman is a global supplier of filtration products and technologies, with a well-recognized brand and strong sector expertise. Whatman has a wide product range of filters and membranes for laboratory, research, life sciences, and medical technology applications. GE Healthcare's Life Sciences business is a leading provider of technologies for cellular and protein science research, and tools used in the manufacture of biopharmaceuticals such as vaccines, cell therapies, and antibodies. The strong strategic fit between the two businesses will offer substantial customer benefits and create significant synergies through complementary product and service offerings.

It is intended that the transaction will be implemented by way of a scheme of arrangement under UK law. The transaction has been recommended unanimously by the directors of Whatman, who have agreed to vote their shares in favor of the transaction. It is expected that the transaction will be completed in the second quarter of 2008.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurologic diseases, and other conditions earlier.

A global leader in filtration technology, Whatman provides innovative life-science products to the scientific community. Whatman has developed total sample preparation solutions through its robust line of filtration devices and membranes. The company's breakthrough protein array technology and FTA technology to capture archive and purify DNA at room temperature, enables it to provide novel solutions for the analytic, health care, and bioscience markets.


Related Links:
GE Healthcare
Whatman

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Digital X-Ray Detector Panel
Acuity G4
Pulmonary Ventilator
OXYMAG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.